Importantly, combined EGFR inhibition with nimotuzumab and gefitinib did not increase EGFR inhibition-related AEs, such as acneiform rash (47.4% vs. 44.9% in gefitinib alone, P = 0.40), diarrhea (35.9 vs. 35.1% in gefitinib alone, P = 0.52), and stomatitis (23.1 vs. 26.0% in gefitinib alone, P = 0.40) (Table 3). The gene discussed is EGFR; the disease is stomatitis.